Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Asset disposition
Quarterly results
CC transcript
ACADIA PHARMACEUTICALS INC (ACAD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ net product sales of $23.2 million - 2Q23 NUPLAZID® net product sales of $142.0 million - Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO, CA, August 2, 2023"
07/18/2023 8-K Quarterly results
05/08/2023 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 - Announced DAYBUE Availability on April 17, 2023 SAN DIEGO, CA, May 8, 2023"
03/13/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/02/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
10/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/08/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results - 1Q22 net sales of $115.5 million, an 8% increase over 1Q21 - Reiterating FY22 net sales guidance of $510 to $560 million - FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO, CA, May 4, 2022"
04/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/28/2022 8-K Quarterly results
12/14/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results - 3Q21 net sales of $131.6 million, a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA"
11/05/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial"
09/02/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results - 2Q21 net sales of $115.2 million, a 5% increase over 2Q20 - Fiscal year 2021 revenue guidance reduced to $480 to $515 million"
06/24/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/27/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/04/2020 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results - 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19"
10/01/2020 8-K Quarterly results
08/25/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
07/20/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
01/13/2020 8-K Investor presentation
Docs: "Presentation of ACADIA Pharmaceuticals Inc., made available on January 13, 2020",
"Presentation of ACADIA Pharmaceuticals Inc., made available on January 13, 2020"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy